Drugs / Personalized neoantigen vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03558945 | Jul 2018 → Nov 2023 | pancreatic neoplasm | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized neoantigen vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03558945 ↗ |
| Modality | Vaccine | “personalized neoantigen peptide-based vaccines” NCT03558945 ↗ |
| Route | Subcutaneous | “personalized neoantigen vaccines will be administered subcutaneously” NCT03558945 ↗ |